Across TCGA pan-cancer cohorts, ANAPC7 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ANAPC7 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ANAPC7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANAPC7 expression acts as an unfavorable survival marker.
STAD, KIRP, and CESC are the cancer types where ANAPC7 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.